Abstract
Frontotemporal Lobar Degeneration (FTLD) is a genetically and pathologically heterogeneous disorder characterized by behavioral change, executive dysfunction and language impairment associated with frontal and temporal lobe degeneration. Three major clinical subtypes have been identified so far, namely behaviour variant Frontotemporal dementia (bvFTD), Semantic Dementia (SD) and Progressive Non-Fluent Aphasia (PNFA). FTLD might also overlap with atypical parkinsonisms or motor neuron disease. Several pathogenetic mutations have been associated with specific pathological and clinical correlates. FTLD associated with either Microtuble Associated Protein Tau (MAPT) or Progranulin (PGRN) mutations is recognised as the most common form of autosomal dominant inherited disorder. However, monogenic mutations account for only about one third of all FTLD cases. Several studies have evaluated the contribution of genetic background in non-monogenic forms of FTLD, with the attempt to establish its role in increasing disease risk and in modulating clinical phenotypes. Specific MAPT and PGRN polymorphisms have been demonstrated to affect disease onset, clinical features and prognosis of FTLD, and genetic variations within other genes appear to play a role in influencing disease risk and clinical expression of FTLD.
The aim of the present review is to discuss the impact and the role of genetic background in non-monogenic forms of FTLD, to highlight new potential pathogenetic and therapeutic targets.
Keywords: Frontotemporal lobar degeneration, frontotemporal dementia, genetics, polymorphism, risk factors, FTLD, MAPT, PGRN, Microtuble Associated Protein Tau, parkinsonisms, non-monogenic
Mini-Reviews in Medicinal Chemistry
Title: Genetic Contributors to Frontotemporal Lobar Degeneration: Beyond Monogenic Disease
Volume: 11 Issue: 11
Author(s): B. Borroni, A. Pilotto, M. Bianchi, N. Gilberti and A. Padovani
Affiliation:
Keywords: Frontotemporal lobar degeneration, frontotemporal dementia, genetics, polymorphism, risk factors, FTLD, MAPT, PGRN, Microtuble Associated Protein Tau, parkinsonisms, non-monogenic
Abstract: Frontotemporal Lobar Degeneration (FTLD) is a genetically and pathologically heterogeneous disorder characterized by behavioral change, executive dysfunction and language impairment associated with frontal and temporal lobe degeneration. Three major clinical subtypes have been identified so far, namely behaviour variant Frontotemporal dementia (bvFTD), Semantic Dementia (SD) and Progressive Non-Fluent Aphasia (PNFA). FTLD might also overlap with atypical parkinsonisms or motor neuron disease. Several pathogenetic mutations have been associated with specific pathological and clinical correlates. FTLD associated with either Microtuble Associated Protein Tau (MAPT) or Progranulin (PGRN) mutations is recognised as the most common form of autosomal dominant inherited disorder. However, monogenic mutations account for only about one third of all FTLD cases. Several studies have evaluated the contribution of genetic background in non-monogenic forms of FTLD, with the attempt to establish its role in increasing disease risk and in modulating clinical phenotypes. Specific MAPT and PGRN polymorphisms have been demonstrated to affect disease onset, clinical features and prognosis of FTLD, and genetic variations within other genes appear to play a role in influencing disease risk and clinical expression of FTLD.
The aim of the present review is to discuss the impact and the role of genetic background in non-monogenic forms of FTLD, to highlight new potential pathogenetic and therapeutic targets.
Export Options
About this article
Cite this article as:
Borroni B., Pilotto A., Bianchi M., Gilberti N. and Padovani A., Genetic Contributors to Frontotemporal Lobar Degeneration: Beyond Monogenic Disease, Mini-Reviews in Medicinal Chemistry 2011; 11 (11) . https://dx.doi.org/10.2174/138955711797068517
DOI https://dx.doi.org/10.2174/138955711797068517 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Curcumin: A Potential Neuroprotective Agent in Parkinson's Disease
Current Pharmaceutical Design New Targets for Therapy in Polyglutamine (polyQ) Expansion Diseases
Current Drug Therapy Role of MicroRNA Genes <i>miR-1000</i> and <i>miR-375</i> in Forming Olfactory Conditional Memory in <i>Drosophila melanogaster</i>
MicroRNA Role of Hexokinase and VDAC in Neurological Disorders
Current Molecular Pharmacology Role of Dendritic Cells in HIV-Immunotherapy
Current HIV Research Protein Aggregation and Self Assembly in Health and Disease
Current Proteomics The Unbiased Search of Biomarkers in Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Editorial (Hot Topic: Neuroprotection and Neuroregeneration in Ischemic Stroke: Emerging Treatment Strategies and Potential Molecular Targets)
Current Drug Targets Executive Function and Diabetes Mellitus - A Stone Left Unturned?
Current Diabetes Reviews Flavonoids Health Benefits and Their Molecular Mechanism
Mini-Reviews in Medicinal Chemistry Pharmacology of Rhein and Advancement in the Synthesis of Its Derivatives
Current Traditional Medicine T Cell-based Therapies for Atherosclerosis
Current Pharmaceutical Design Hormones in the Mentally Disturbed Brain: Steroids and Peptides in the Development and Treatment of Psychopathology
Central Nervous System Agents in Medicinal Chemistry Mapping Exchangeable Protons to Monitor Protein Alterations in the Brain of an Alzheimer’s Disease Mouse Model by Using MRI
Current Alzheimer Research Astrocytes: From the Physiology to the Disease
Current Alzheimer Research Nanomedicine Strategies for Sustained, Controlled and Targeted Treatment of Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry Prevalence and Predictors of Overweight and Obesity in Patients with Pituitary Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Perception of Symptoms in Hypertensive Patients and the Relevance to the Application of Anti- Hypertensive Drug Therapy
Current Pharmaceutical Design Alzheimers and Dementia in the Oldest-Old: A Century of Challenges
Current Alzheimer Research A PPAR-β/δ Agonist is Neuroprotective and Decreases Cognitive Impairment in a Rodent Model of Parkinson’s Disease
Current Neurovascular Research